Mirae Asset Global Investments’s Regeneron Pharmaceuticals REGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$58.4M Buy
93,632
+9,024
+11% +$6.14M 0.09% 148
2026
Q1
$65.4M Buy
84,608
+7,404
+10% +$5.67M 0.02% 96
2025
Q4
$59.6M Buy
77,204
+14,635
+23% +$9.94M 0.17% 105
2025
Q3
$35.2M Buy
62,569
+5,403
+9% +$3.05M 0.11% 151
2025
Q2
$30M Buy
57,166
+4,080
+8% +$2.28M 0.1% 158
2025
Q1
$33.3M Sell
53,086
-2,340
-4% -$1.61M 0.14% 126
2024
Q4
$38.3M Buy
55,426
+9,845
+22% +$8.26M 0.16% 112
2024
Q3
$46.9M Buy
45,581
+7,428
+19% +$8.27M 0.21% 90
2024
Q2
$38.3M Sell
38,153
-83,172
-69% -$80.6M 0.19% 90
2024
Q1
$104M Sell
121,325
-2,992
-2% -$2.85M 0.23% 84
2023
Q4
$109M Sell
124,317
-936
-0.7% -$771K 0.22% 97
2023
Q3
$103M Buy
125,253
+15,751
+14% +$12.4M 0.23% 90
2023
Q2
$78.7M Sell
109,502
-98
-0.1% -$75.6K 0.17% 124
2023
Q1
$90.1M Sell
109,600
-1,317
-1% -$993K 0.21% 91
2022
Q4
$80M Sell
110,917
-6,958
-6% -$5.13M 0.21% 106
2022
Q3
$81.2M Sell
117,875
-27,536
-19% -$17.3M 0.22% 96
2022
Q2
$86M Buy
145,411
+32,648
+29% +$21.2M 0.22% 94
2022
Q1
$78.8M Buy
112,763
+21,852
+24% +$13.8M 0.17% 137
2021
Q4
$57.4M Buy
90,911
+9,720
+12% +$5.98M 0.12% 189
2021
Q3
$49.1M Buy
81,191
+11,955
+17% +$7.42M 0.12% 207
2021
Q2
$38.7M Buy
69,236
+10,597
+18% +$5.37M 0.11% 239
2021
Q1
$27.7M Sell
58,639
-13,047
-18% -$6.35M 0.1% 270
2020
Q4
$34.6M Buy
71,686
+6,063
+9% +$3.27M 0.13% 194
2020
Q3
$36.7M Buy
65,623
+7,202
+12% +$4.37M 0.18% 120
2020
Q2
$36.4M Buy
58,421
+7,424
+15% +$4.21M 0.22% 103
2020
Q1
$24.9M Buy
50,997
+8,401
+20% +$3.47M 0.19% 110
2019
Q4
$16M Buy
42,596
+6,123
+17% +$2.06M 0.1% 248
2019
Q3
$10.1M Buy
36,473
+1,057
+3% +$313K 0.07% 311
2019
Q2
$11.1M Sell
35,416
-52,790
-60% -$17.6M 0.08% 278
2019
Q1
$36.2M Sell
88,206
-1,371
-2% -$565K 0.26% 87
2018
Q4
$33.5M Buy
89,577
+54,889
+158% +$20.1M 0.3% 69
2018
Q3
$14M Buy
34,688
+16,774
+94% +$6.38M 0.1% 199
2018
Q2
$6.17M Buy
17,914
+4,695
+36% +$1.47M 0.08% 154
2018
Q1
$4.55M Buy
13,219
+2,878
+28% +$1M 0.06% 199
2017
Q4
$3.89M Buy
10,341
+3,887
+60% +$1.57M 0.05% 225
2017
Q3
$2.85M Buy
6,454
+1,325
+26% +$630K 0.05% 271
2017
Q2
$2.56M Buy
5,129
+567
+12% +$248K 0.04% 268
2017
Q1
$1.77M Buy
4,562
+2,621
+135% +$972K 0.03% 303
2016
Q4
$713K Sell
1,941
-2,734
-58% -$1.04M 0.02% 360
2016
Q3
$1.88M Sell
4,675
-767
-14% -$308K 0.04% 248
2016
Q2
$1.9M Sell
5,442
-4,904
-47% -$1.89M 0.05% 221
2016
Q1
$3.73M Buy
10,346
+1,825
+21% +$752K 0.1% 152
2015
Q4
$4.63M Buy
8,521
+1,771
+26% +$960K 0.15% 130
2015
Q3
$3.14M Buy
6,750
+79
+1% +$42.4K 0.13% 153
2015
Q2
$3.4M Buy
6,671
+608
+10% +$297K 0.11% 146
2015
Q1
$2.74M Buy
6,063
+3,607
+147% +$1.53M 0.09% 167
2014
Q4
$1.01M Buy
2,456
+40
+2% +$15.7K 0.04% 267
2014
Q3
$871K Buy
+2,416
New +$810K 0.03% 295

Other funds holding REGN

Mirae Asset Global Investments's REGN Position: Q2 2026 in Review

Mirae Asset Global Investments increased its Regeneron Pharmaceuticals (REGN) stake by 11% in Q2 2026, buying an estimated $6.14M and bringing the position to 93,632 shares worth $58.4M. The position accounts for 0.09% of the portfolio, ranked #148.

Mirae Asset Global Investments first reported a position in REGN in Q3 2014 and has held it in 48 quarters since. The position peaked at $109M in Q4 2023. 336 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Mirae Asset Global Investments held 93,632 shares of Regeneron Pharmaceuticals worth $58.4M as of Q2 2026.
  • Mirae Asset Global Investments bought 9,024 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $6.14M.
  • Regeneron Pharmaceuticals made up 0.09% of Mirae Asset Global Investments's portfolio in Q2 2026, its #148 holding.
  • Mirae Asset Global Investments first reported a position in Regeneron Pharmaceuticals in Q3 2014 and has held it in 48 quarters since.
  • Mirae Asset Global Investments's Regeneron Pharmaceuticals position peaked at $109M in Q4 2023.
  • 336 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Mirae Asset Global Investments's 13F filing for Q2 2026, filed 22 Jul 2026.